ADRO - Aduro Biotech Stock Price, News & Analysis

$9.10 -0.05 (-0.55 %)
(As of 11/23/2017 04:10 AM ET)
Previous Close$9.15
Today's Range$8.95 - $9.22
52-Week Range$6.01 - $14.25
Volume357,500 shs
Average Volume406,322 shs
Market Capitalization$707.33 million
P/E RatioN/A
Dividend YieldN/A
Beta3.41

About Aduro Biotech (NASDAQ:ADRO)

Aduro Biotech logoAduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADRO
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio10.62%
Quick Ratio10.62%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$50.68 million
Price / Sales13.88
Cash FlowN/A
Price / CashN/A
Book Value$3.32 per share
Price / Book2.74

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.36)
Net Income$-91,140,000.00
Net Margins-548.92%
Return on Equity-39.28%
Return on Assets-21.15%

Miscellaneous

Employees158
Outstanding Shares77,300,000

Frequently Asked Questions for Aduro Biotech (NASDAQ:ADRO)

What is Aduro Biotech's stock symbol?

Aduro Biotech trades on the NASDAQ under the ticker symbol "ADRO."

How were Aduro Biotech's earnings last quarter?

Aduro Biotech, Inc. (NASDAQ:ADRO) released its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.03. The biotechnology company earned $3.79 million during the quarter, compared to analysts' expectations of $4.04 million. Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. Aduro Biotech's quarterly revenue was up .0% on a year-over-year basis. During the same period last year, the firm earned ($0.54) earnings per share. View Aduro Biotech's Earnings History.

Where is Aduro Biotech's stock going? Where will Aduro Biotech's stock price be in 2017?

8 analysts have issued 1 year price objectives for Aduro Biotech's shares. Their predictions range from $15.00 to $30.00. On average, they expect Aduro Biotech's stock price to reach $20.17 in the next twelve months. View Analyst Ratings for Aduro Biotech.

What are Wall Street analysts saying about Aduro Biotech stock?

Here are some recent quotes from research analysts about Aduro Biotech stock:

  • 1. According to Zacks Investment Research, "Aduro’s lead candidate, CRS-207, being evaluated for a number of cancer indications, bodes well for long-term growth. Moreover, its collaboration agreements with large pharma companies, Novartis, Johnson & Johnson and Incyte are big positives for the company. Aduro has a broad and a promising pipeline of novel immunotherapies under development for the treatment of a variety of cancers. Aduro’s efforts to develop its pipeline are encouraging. However, Aduro depends largely on funds generated from collaboration and license agreements, government grants and other payments for the development of its pipeline candidates. Thus, inability to secure sufficient funding could hinder its pipeline progress. Aduro’s shares underperformed the industry in the last one year. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters." (8/2/2017)
  • 2. Canaccord Genuity analysts commented, "1Q17 results recap. Adjusted non-GAAP revenue (excluding the individual commercial business) grew 4.4% year over year. Adjusted MLR was 85.2% compared to 85.0% a year ago. MLR benefitted from the exit of certain Medicare markets, which was offset to some degree by lower prior period development when compared to a year ago. Cost trends appear to be in check, consistent with other publicly-traded health insurers." (5/3/2017)
  • 3. FBR & Co analysts commented, "Aduro Biotech, Inc.’s (ADRO) cancer immunotherapy platform triggers both innate and adaptive immunity, resulting in a broad and potent multi-pronged immune response. The company’s engineered live, attenuated, double-deleted (LADD) Listeria monocytogenes program is capable of inducing an antigen-specific adaptive T-cell response (CD8+ and CD4+), as well as an innate immune response that includes cytokines, chemokines, gamma delta T cells, and NK cells. The company’s STING (Stimulator of Interferon Genes, driven by cytosolic DNA) platform induces dendritic cells and enhances an anti-tumor T-cell response in the tumor microenvironment. Aduro’s third technology platform is B-select, based on clonal expansion of B cells producing highly selective and functional antibodies against targets that regulate the immune response. Given that the future of cancer immunotherapy points to combinations, Aduro’s programs are complementary combination approaches that activate distinct mechanisms of actions that could be synergistic." (3/7/2017)

Who are some of Aduro Biotech's key competitors?

Who are Aduro Biotech's key executives?

Aduro Biotech's management team includes the folowing people:

  • Stephen T. Isaacs, Chairman of the Board, President and Chief Executive Officer (Age 68)
  • Gregory W. Schafer, Chief Operating Officer (Age 52)
  • Blaine Templeman, Executive Vice President, General Counsel, Secretary (Age 51)
  • Dirk G. Brockstedt, Executive Vice President of Research and Development (Age 48)
  • Jennifer Lew CPA, Senior Vice President - Finance (Age 44)
  • Andrea van Elsas Ph.D., Chief Scientific Officer
  • Natalie R. Sacks, Chief Medical Officer (Age 52)
  • Stephanie Monaghan O'Brien J.D., Lead Independent Director (Age 58)
  • Gerald Chan Ph.D., Independent Director (Age 66)
  • William M. Greenman, Independent Director (Age 50)

When did Aduro Biotech IPO?

(ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who owns Aduro Biotech stock?

Aduro Biotech's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include MORNINGSIDE VENTURE (VI) INVESTMENTS LTD (12.47%), Harvard Management Co. Inc. (8.43%), Baillie Gifford & Co. (0.74%), Oak Ridge Investments LLC (0.56%), Artal Group S.A. (0.26%) and Bank of New York Mellon Corp (0.23%). Company insiders that own Aduro Biotech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro Biotech.

Who sold Aduro Biotech stock? Who is selling Aduro Biotech stock?

Aduro Biotech's stock was sold by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC and Russell Investments Group Ltd.. Company insiders that have sold Aduro Biotech company stock in the last year include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Stephen T Isaacs and Thomas W Dubensky. View Insider Buying and Selling for Aduro Biotech.

Who bought Aduro Biotech stock? Who is buying Aduro Biotech stock?

Aduro Biotech's stock was acquired by a variety of institutional investors in the last quarter, including Harvard Management Co. Inc., Baillie Gifford & Co., Artal Group S.A., Point72 Asset Management L.P., Allianz Asset Management GmbH, Wells Fargo & Company MN, Bank of New York Mellon Corp and Trexquant Investment LP. View Insider Buying and Selling for Aduro Biotech.

How do I buy Aduro Biotech stock?

Shares of Aduro Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aduro Biotech's stock price today?

One share of Aduro Biotech stock can currently be purchased for approximately $9.10.

How big of a company is Aduro Biotech?

Aduro Biotech has a market capitalization of $707.33 million and generates $50.68 million in revenue each year. The biotechnology company earns $-91,140,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Aduro Biotech employs 158 workers across the globe.

How can I contact Aduro Biotech?

Aduro Biotech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]


MarketBeat Community Rating for Aduro Biotech (ADRO)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about Aduro Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Aduro Biotech (NASDAQ:ADRO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 8 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.17 (121.61% upside)

Consensus Price Target History for Aduro Biotech (NASDAQ:ADRO)

Price Target History for Aduro Biotech (NASDAQ:ADRO)

Analysts' Ratings History for Aduro Biotech (NASDAQ:ADRO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/1/2017HC WainwrightSet Price TargetBuy$18.00N/AView Rating Details
10/30/2017Oppenheimer Holdings, Inc.Initiated CoverageBuy$15.00N/AView Rating Details
10/2/2017William BlairReiterated RatingOutperformHighView Rating Details
8/3/2017Canaccord GenuitySet Price TargetBuy$30.00LowView Rating Details
7/18/2017Cowen and CompanyInitiated CoverageOutperformLowView Rating Details
5/1/2017Rodman & RenshawInitiated CoverageBuy -> Buy$18.00LowView Rating Details
3/7/2017FBR & CoReiterated RatingBuy$23.00N/AView Rating Details
3/7/2017Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
10/24/2016Leerink SwannSet Price TargetBuy$14.00N/AView Rating Details
3/15/2016Bank of America CorporationDowngradeBuy -> Underperform$32.00 -> $14.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Aduro Biotech (NASDAQ:ADRO)

Earnings by Quarter for Aduro Biotech (NASDAQ:ADRO)

Earnings History by Quarter for Aduro Biotech (NASDAQ ADRO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017Q3 2017($0.30)($0.33)$4.04 million$3.79 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.25)($0.27)$3.98 million$5.90 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.39)($0.32)$3.74 million$3.77 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.40)($0.44)$3.83 million$3.88 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.45)($0.54)$3.99 million$3.79 millionViewN/AView Earnings Details
8/3/2016Q2 2016($0.18)$0.03$25.24 million$39.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.25)($0.45)$13.47 million$4.03 millionViewN/AView Earnings Details
3/8/2016Q415($0.15)$0.04$17.55 million$34.38 millionViewN/AView Earnings Details
11/23/2015Q3($0.08)$0.01$15.80 million$19.15 millionViewN/AView Earnings Details
8/10/2015Q215($0.01)($0.18)$1.00 million$9.90 millionViewN/AView Earnings Details
5/28/2015Q115($0.08)($39.97)$12.03 million$9.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aduro Biotech (NASDAQ:ADRO)
2017 EPS Consensus Estimate: ($1.51)
2018 EPS Consensus Estimate: ($1.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.39)($0.35)($0.38)
Q2 20173($0.41)($0.31)($0.38)
Q3 20174($0.43)($0.30)($0.38)
Q4 20174($0.46)($0.32)($0.38)
Q1 20183($0.41)($0.24)($0.34)
Q2 20183($0.42)($0.19)($0.33)
Q3 20183($0.43)($0.20)($0.35)
Q4 20183($0.43)($0.21)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aduro Biotech (NASDAQ:ADRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aduro Biotech (NASDAQ ADRO)

Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 43.10%
Insider Trades by Quarter for Aduro Biotech (NASDAQ:ADRO)
Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

Insider Trades by Quarter for Aduro Biotech (NASDAQ ADRO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/17/2017Blaine TemplemanVPSell243$8.85$2,150.55View SEC Filing  
11/15/2017Jennifer LewInsiderSell6,600$8.95$59,070.00View SEC Filing  
11/13/2017Dirk G BrockstedtEVPSell5,877$8.00$47,016.00View SEC Filing  
11/13/2017Stephen T IsaacsInsiderSell19,800$7.97$157,806.00View SEC Filing  
11/10/2017Dirk G BrockstedtEVPSell1,815$8.01$14,538.15View SEC Filing  
11/10/2017Stephen T IsaacsCEOSell16,400$7.96$130,544.00View SEC Filing  
11/7/2017Stephen T IsaacsInsiderSell20,200$7.98$161,196.00View SEC Filing  
11/6/2017Dirk G BrockstedtEVPSell4,123$8.04$33,148.92View SEC Filing  
11/6/2017Gregory W SchaferCOOSell20,000$7.97$159,400.00View SEC Filing  
10/2/2017Dirk G BrockstedtEVPSell10,000$10.59$105,900.00View SEC Filing  
10/2/2017Gregory W SchaferCOOSell20,000$10.75$215,000.00View SEC Filing  
10/2/2017Jennifer LewInsiderSell6,600$10.61$70,026.00View SEC Filing  
10/2/2017Stephen T IsaacsCEOSell40,000$10.78$431,200.00View SEC Filing  
9/18/2017Blaine TemplemanVPSell2,884$11.20$32,300.80View SEC Filing  
9/13/2017Blaine TemplemanVPSell3,557$10.99$39,091.43View SEC Filing  
9/13/2017Elsas Andrea VanInsiderSell4,922$10.99$54,092.78View SEC Filing  
9/13/2017Gregory W SchaferCOOSell4,859$10.99$53,400.41View SEC Filing  
9/1/2017Dirk G BrockstedtEVPSell10,000$11.69$116,900.00View SEC Filing  
9/1/2017Gregory W SchaferCOOSell20,000$11.70$234,000.00View SEC Filing  
9/1/2017Jennifer LewInsiderSell6,600$11.70$77,220.00View SEC Filing  
8/11/2017Thomas W DubenskyInsiderSell50,000$11.38$569,000.00View SEC Filing  
8/10/2017Thomas W DubenskyInsiderSell40,912$11.43$467,624.16View SEC Filing  
8/8/2017Gregory W SchaferCOOSell40,000$12.17$486,800.00View SEC Filing  
8/7/2017Dirk G BrockstedtEVPSell10,000$12.18$121,800.00View SEC Filing  
8/7/2017Gregory W SchaferCOOSell25,811$12.17$314,119.87View SEC Filing  
8/7/2017Jennifer LewInsiderSell6,600$12.17$80,322.00View SEC Filing  
8/7/2017Stephen T IsaacsCEOSell40,000$12.19$487,600.00View SEC Filing  
7/6/2017Thomas W DubenskyInsiderSell50,000$11.33$566,500.00View SEC Filing  
7/5/2017Stephen T IsaacsInsiderSell40,000$11.06$442,400.00View SEC Filing  
7/3/2017Dirk G BrockstedtEVPSell10,000$11.02$110,200.00View SEC Filing  
7/3/2017Jennifer LewInsiderSell12,000$11.14$133,680.00View SEC Filing  
6/28/2017Gregory W SchaferCOOSell40,000$11.26$450,400.00View SEC Filing  
6/28/2017Jennifer LewInsiderSell12,000$11.19$134,280.00View SEC Filing  
6/19/2017Stephen T IsaacsInsiderSell40,000$10.50$420,000.00View SEC Filing  
6/5/2017Thomas W DubenskyInsiderSell144,301$10.03$1,447,339.03View SEC Filing  
5/17/2017Blaine TemplemanVPSell1,648$9.65$15,903.20View SEC Filing  
5/17/2017Dirk G. BrockstedtEVPSell1,011$9.65$9,756.15View SEC Filing  
5/16/2017Stephen T. IsaacsCEOSell16,673$10.00$166,730.00View SEC Filing  
5/16/2017Stephen T. IsaacsinsiderSell27,273$10.01$273,002.73View SEC Filing  
5/15/2017Stephen T. IsaacsCEOSell10,600$10.01$106,106.00View SEC Filing  
5/12/2017Thomas W DubenskyInsiderSell5,699$9.92$56,534.08View SEC Filing  
5/11/2017Dirk G BrockstedtEVPSell8,000$9.72$77,760.00View SEC Filing  
4/3/2017Dirk G BrockstedtEVPSell8,000$10.71$85,680.00View SEC Filing  
4/3/2017Stephen T IsaacsInsiderSell27,273$10.28$280,366.44View SEC Filing  
3/13/2017Stephen T IsaacsInsiderSell27,273$11.35$309,548.55View SEC Filing  
3/9/2017Dirk G BrockstedtEVPSell8,000$11.00$88,000.00View SEC Filing  
3/9/2017Thomas W DubenskyInsiderSell25,000$10.96$274,000.00View SEC Filing  
1/17/2017Dirk G BrockstedtEVPSell8,000$11.86$94,880.00View SEC Filing  
1/11/2017Blaine TemplemanVPSell3,785$11.95$45,230.75View SEC Filing  
1/3/2017Stephen T IsaacsInsiderSell27,273$11.12$303,275.76View SEC Filing  
12/1/2016Thomas W DubenskyInsiderSell25,000$10.94$273,500.00View SEC Filing  
11/14/2016Ross HaghighatDirectorSell7,088$15.50$109,864.00View SEC Filing  
10/3/2016Stephen T IsaacsCEOSell27,273$12.67$345,548.91View SEC Filing  
10/3/2016Thomas W DubenskyInsiderSell25,000$12.68$317,000.00View SEC Filing  
9/19/2016Jennifer LewInsiderSell6,360$14.95$95,082.00View SEC Filing  
9/1/2016Thomas W DubenskyInsiderSell25,000$14.03$350,750.00View SEC Filing  
8/11/2016Thomas W DubenskyInsiderSell25,000$15.18$379,500.00View SEC Filing  
7/5/2016Thomas W DubenskyInsiderSell25,000$11.61$290,250.00View SEC Filing  
5/16/2016Thomas W. DubenskyInsiderSell905$8.20$7,421.00View SEC Filing  
1/11/2016Dirk G. BrockstedtVPSell22,000$21.77$478,940.00View SEC Filing  
1/8/2016Gregory W. SchaferCOOSell20,000$23.58$471,600.00View SEC Filing  
1/6/2016Jennifer LewVPSell5,242$25.71$134,771.82View SEC Filing  
1/5/2016Stephen T. IsaacsCEOSell25,000$26.31$657,750.00View SEC Filing  
1/4/2016Thomas W. DubenskyinsiderSell15,000$26.37$395,550.00View SEC Filing  
12/7/2015Gregory W. SchaferCOOSell25,000$29.74$743,500.00View SEC Filing  
12/3/2015Jennifer LewVPSell5,242$29.85$156,473.70View SEC Filing  
12/1/2015Stephen T. IsaacsCEOSell25,000$29.11$727,750.00View SEC Filing  
12/1/2015Thomas W. DubenskyinsiderSell30,000$29.27$878,100.00View SEC Filing  
11/18/2015Jennifer LewVPSell6,712$28.52$191,426.24View SEC Filing  
11/17/2015Gregory W. SchaferCOOSell26,470$28.15$745,130.50View SEC Filing  
11/17/2015Thomas W. DubenskyinsiderSell31,470$28.27$889,656.90View SEC Filing  
11/16/2015Stephen T. IsaacsCEOSell25,000$27.54$688,500.00View SEC Filing  
4/20/2015Jennifer LewVPBuy2,000$17.00$34,000.00View SEC Filing  
4/20/2015Venture (Vi) Inves MorningsideMajor ShareholderBuy441,176$17.00$7,499,992.00View SEC Filing  
4/20/2015William Mariner GreenmanDirectorBuy3,000$17.00$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aduro Biotech (NASDAQ ADRO)

Source:
DateHeadline
Aduro Biotech Scientific Advisor and Co-Founder of Aduro Biotech Europe Wiebe Olijve Honored with Royal Decoration - GlobeNewswire (press release)Aduro Biotech Scientific Advisor and Co-Founder of Aduro Biotech Europe Wiebe Olijve Honored with Royal Decoration - GlobeNewswire (press release)
globenewswire.com - November 21 at 3:02 AM
Aduro Biotech, Inc. (ADRO) Given Consensus Rating of "Buy" by AnalystsAduro Biotech, Inc. (ADRO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 19 at 5:50 AM
Insider Selling: Aduro Biotech, Inc. (ADRO) Insider Sells 6,600 Shares of StockInsider Selling: Aduro Biotech, Inc. (ADRO) Insider Sells 6,600 Shares of Stock
www.americanbankingnews.com - November 17 at 9:28 PM
ETFs with exposure to Aduro BioTech, Inc. : November 16, 2017ETFs with exposure to Aduro BioTech, Inc. : November 16, 2017
finance.yahoo.com - November 16 at 3:45 PM
Aduro Biotech, Inc. (ADRO) EVP Dirk G. Brockstedt Sells 1,815 SharesAduro Biotech, Inc. (ADRO) EVP Dirk G. Brockstedt Sells 1,815 Shares
www.americanbankingnews.com - November 14 at 10:14 PM
Aduro Biotech, Inc. (ADRO) EVP Sells $47,016.00 in StockAduro Biotech, Inc. (ADRO) EVP Sells $47,016.00 in Stock
www.americanbankingnews.com - November 14 at 9:23 PM
Aduro Biotech, Inc. (ADRO) CEO Sells $130,544.00 in StockAduro Biotech, Inc. (ADRO) CEO Sells $130,544.00 in Stock
www.americanbankingnews.com - November 14 at 8:52 PM
Aduro Biotech, Inc. (ADRO) Insider Stephen T. Isaacs Sells 19,800 SharesAduro Biotech, Inc. (ADRO) Insider Stephen T. Isaacs Sells 19,800 Shares
www.americanbankingnews.com - November 14 at 8:52 PM
Aduro Biotech (ADRO) Reports Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604Aduro Biotech (ADRO) Reports Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604
www.streetinsider.com - November 11 at 12:27 PM
Aduro Biotech, Inc. (ADRO) Expected to Announce Quarterly Sales of $4.32 MillionAduro Biotech, Inc. (ADRO) Expected to Announce Quarterly Sales of $4.32 Million
www.americanbankingnews.com - November 11 at 4:39 AM
Aduro Biotech (ADRO) Reports Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604 - StreetInsider.comAduro Biotech (ADRO) Reports Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604 - StreetInsider.com
www.streetinsider.com - November 10 at 8:08 AM
Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604
finance.yahoo.com - November 10 at 8:08 AM
Aduro Biotech, Inc. (ADRO) Expected to Announce Earnings of -$0.36 Per ShareAduro Biotech, Inc. (ADRO) Expected to Announce Earnings of -$0.36 Per Share
www.americanbankingnews.com - November 9 at 7:15 PM
Insider Selling: Aduro Biotech, Inc. (ADRO) EVP Sells 4,123 Shares of StockInsider Selling: Aduro Biotech, Inc. (ADRO) EVP Sells 4,123 Shares of Stock
www.americanbankingnews.com - November 8 at 9:42 PM
Aduro Biotech, Inc. (ADRO) COO Gregory W. Schafer Sells 20,000 SharesAduro Biotech, Inc. (ADRO) COO Gregory W. Schafer Sells 20,000 Shares
www.americanbankingnews.com - November 8 at 9:21 PM
Aduro Biotech, Inc. (ADRO) Insider Stephen T. Isaacs Sells 20,200 SharesAduro Biotech, Inc. (ADRO) Insider Stephen T. Isaacs Sells 20,200 Shares
www.americanbankingnews.com - November 8 at 9:21 PM
Coal demand in Indonesia is on the upswing: executiveCoal demand in Indonesia is on the upswing: executive
finance.yahoo.com - November 7 at 3:22 AM
ETFs with exposure to Aduro BioTech, Inc. : November 6, 2017ETFs with exposure to Aduro BioTech, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 4:16 PM
ETFs with exposure to Aduro BioTech, Inc. : November 6, 2017ETFs with exposure to Aduro BioTech, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 4:16 PM
Leerink Swann Weighs in on Aduro Biotech, Inc.s FY2017 Earnings (ADRO)Leerink Swann Weighs in on Aduro Biotech, Inc.'s FY2017 Earnings (ADRO)
www.americanbankingnews.com - November 6 at 8:06 AM
FY2017 Earnings Estimate for Aduro Biotech, Inc. (ADRO) Issued By William BlairFY2017 Earnings Estimate for Aduro Biotech, Inc. (ADRO) Issued By William Blair
www.americanbankingnews.com - November 6 at 8:06 AM
Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017
finance.yahoo.com - November 2 at 3:34 PM
FY2017 Earnings Forecast for Aduro Biotech, Inc. Issued By Oppenheimer Holdings (ADRO)FY2017 Earnings Forecast for Aduro Biotech, Inc. Issued By Oppenheimer Holdings (ADRO)
www.americanbankingnews.com - November 2 at 9:48 AM
Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues MissAduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss
finance.yahoo.com - November 2 at 1:58 AM
Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss - NasdaqAduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss - Nasdaq
www.nasdaq.com - November 1 at 3:51 PM
Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting - GlobeNewswire (press release)Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting - GlobeNewswire (press release)
globenewswire.com - November 1 at 3:51 PM
Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual MeetingAduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 3:50 PM
Aduro Biotech, Inc. (ADRO) Announces  Earnings Results, Misses Expectations By $0.03 EPSAduro Biotech, Inc. (ADRO) Announces Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - November 1 at 1:36 PM
Aduro Biotech, Inc. Expected to Earn Q3 2017 Earnings of ($0.38) Per Share (ADRO)Aduro Biotech, Inc. Expected to Earn Q3 2017 Earnings of ($0.38) Per Share (ADRO)
www.americanbankingnews.com - November 1 at 8:44 AM
Aduro Biotech Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Aduro Biotech Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - October 31 at 9:43 PM
Aduro Biotech reports 3Q lossAduro Biotech reports 3Q loss
finance.yahoo.com - October 31 at 9:43 PM
Aduro Biotech Reports Third Quarter 2017 Financial ResultsAduro Biotech Reports Third Quarter 2017 Financial Results
finance.yahoo.com - October 31 at 4:39 PM
Aduro Biotech (ADRO) vs. Its Rivals Critical SurveyAduro Biotech (ADRO) vs. Its Rivals Critical Survey
www.americanbankingnews.com - October 31 at 3:20 AM
Oppenheimer Holdings Inc. Begins Coverage on Aduro Biotech, Inc. (ADRO)Oppenheimer Holdings Inc. Begins Coverage on Aduro Biotech, Inc. (ADRO)
www.americanbankingnews.com - October 30 at 6:34 PM
ETFs with exposure to Aduro BioTech, Inc. : October 25, 2017ETFs with exposure to Aduro BioTech, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 4:22 PM
Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on ... - GlobeNewswire (press release)Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on ... - GlobeNewswire (press release)
globenewswire.com - October 17 at 9:11 PM
Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on Lung CancerAduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on Lung Cancer
finance.yahoo.com - October 17 at 4:08 PM
Adverum Biotechnologies (ADVM) in Focus: Stock Moves 9.7% HigherAdverum Biotechnologies (ADVM) in Focus: Stock Moves 9.7% Higher
www.zacks.com - October 13 at 3:26 PM
Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancers 32nd Annual ... - GlobeNewswire (press release)Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer's 32nd Annual ... - GlobeNewswire (press release)
globenewswire.com - October 9 at 9:39 PM
Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer’s 32nd Annual MeetingAduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
finance.yahoo.com - October 9 at 4:38 PM
Ligand (LGND) Signs Deal to Acquire Crystal BioscienceLigand (LGND) Signs Deal to Acquire Crystal Bioscience
finance.yahoo.com - October 5 at 12:27 PM
Jennifer Lew Sells 6,600 Shares of Aduro Biotech, Inc. (ADRO) StockJennifer Lew Sells 6,600 Shares of Aduro Biotech, Inc. (ADRO) Stock
www.americanbankingnews.com - October 4 at 10:42 PM
Dirk G. Brockstedt Sells 10,000 Shares of Aduro Biotech, Inc. (ADRO) StockDirk G. Brockstedt Sells 10,000 Shares of Aduro Biotech, Inc. (ADRO) Stock
www.americanbankingnews.com - October 4 at 10:24 PM
Insider Selling: Aduro Biotech, Inc. (ADRO) COO Sells 20,000 Shares of StockInsider Selling: Aduro Biotech, Inc. (ADRO) COO Sells 20,000 Shares of Stock
www.americanbankingnews.com - October 4 at 10:22 PM
Insider Selling: Aduro Biotech, Inc. (ADRO) CEO Sells 40,000 Shares of StockInsider Selling: Aduro Biotech, Inc. (ADRO) CEO Sells 40,000 Shares of Stock
www.americanbankingnews.com - October 4 at 10:22 PM
Aduro Biotech, Inc. (ADRO) Receives Outperform Rating from William BlairAduro Biotech, Inc. (ADRO) Receives Outperform Rating from William Blair
www.americanbankingnews.com - October 2 at 11:24 AM
Aduro Biotech, Inc. (ADRO) Receives Average Recommendation of "Buy" from AnalystsAduro Biotech, Inc. (ADRO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 30 at 8:52 AM
Aduro Biotech (ADRO) Reports First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD - StreetInsider.comAduro Biotech (ADRO) Reports First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD - StreetInsider.com
www.streetinsider.com - September 29 at 3:10 PM
Trial has begun in Patients with Metastatic Colorectal Cancer Who Have Few Treatment OptionsTrial has begun in Patients with Metastatic Colorectal Cancer Who Have Few Treatment Options
globenewswire.com - September 28 at 1:37 AM
Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and LymphomasAduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas
finance.yahoo.com - September 28 at 1:37 AM

Social Media

Financials

Chart

Aduro Biotech (NASDAQ ADRO) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.